Lupin is prepping a $1B US deal spree; Protagonist raising $60M for trial work

→  Coming off of a $150 million deal to buy Symbiomix, Mumbai-based Lupin says it’s planning a $1 billion deal spree aimed at building a women’s health group in the US.

→ Protagonist Therapeutics $PTGX is raising $60 million through a private offering. The money will be earmarked for its clinical work on three drug candidates: PTG-100, PTG-200, and PTG-300.

→ AstraZeneca spinoff Entasis has bagged its second CARB-X award for its work on new antibiotics. The Waltham, MA-based biotech gets $3.8 million initially plus a shot at another $6.3 million.

→ Holliston, MA-based Biostage is blaming a failed financing deal for its financial woes, forcing the company to lay off 17 staffers — 71% of its workforce. The company works on bioengineered organ transplants.

→ The FDA is giving Eli Lilly’s abemaciclib a priority review for advanced breast cancer. The agency came through with the accelerated review after it looked over the MONARCH 3 data.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->